FDA’s Drug Safety Office Is Already Independent, CDER Director Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting CDER Director Galson responds to calls for greater independence of drug safety functions by noting that both the Office of Drug Safety and Office of New Drugs report directly to him. FDA will “continue its longstanding practice of assessing the safety of all drugs” using “sound science,” Galson says.